MicrobiologybioRxivPreprint
Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way
O. A. Chaves, C. Q. Sacramento, N. Fintelman-Rodrigues…·T. M. L. Souza
This study shows apixaban inhibits SARS-CoV-2 replication by targeting its Mpro protease non-competitively, with higher potency than boceprevir.
DOI 10.1101/2021.09.23.461605